Loading live market data…

CAMP4 Therapeutics Corporation

NASDAQ:CAMP

$4.45 USD

-$0.05 (-1.11%)

Volume
164.45K
Average Volume
172K
Market Capitalization
$94.52M
P/E Ratio
-1.96
Dividend Yield
0.00%
Price Target
$6.50
Year High
$7.75
Year Low
$1.32
Day High
Day Low
Payout Ratio
$0.00
Current Ratio
$6.15

Industry, Sector & symbol

Stock Exchange NASDAQ
CEO Joshua Mandel-Brehm
Industry Biotechnology
Sector Healthcare
Current Symbol CAMP
CUSIP 13463J101
CIK 0001736730
Web https://www.camp4tx.com
Phone 617-651-8867
Currency USD
Employees 48
Country US

Liquidity

Debt-to-Equity Ratio 0.07
Payout Ratio 0.00
Current Ratio 6.15
Quick Ratio 6.15
Cash Ratio 5.97

Sales & Book Value

Annual Sales $3.5M
Price / Sales 24.03
Cash Flow -0.45
Price / Cash Flow -3.60
Price / Book 8.34

Price Target and Rating

Average Stock Price Forecast $6.50
High Stock Price Forecast $6.50
Low Stock Price Forecast $6.50
Forecast Upside/Downside -31.54%
Consensus Rating Strong Sell
Rating Score(0-5) 1
Research Coverage 24 Analysts

Profitability

EPS (Most Recent Fiscal Year) $-2.65
Trailing P/E Ratio -1.96
PEG Ratio -0.09
P/E Growth -0.09
Net Income $-80.4M
Net Margin -2193.72%
Pretax Margin -2193.72%
Return on Equity -194.74%
Return on Assets -81.84%

Financials Score

AltmanZ Score -4.06
Piotroski Score 2.00
Working Capital 85.57M
Total Assets 105.46M
Ebit -53.97M
Market Cap 91.97M
Total Liabilities 74.56M

Poll Results

About CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Stock

CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients. ...

CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-06-19 16:05:00

CAMBRIDGE, Mass., June 19, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on June 15, 2026 (the “Grant Date”), the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 39,000 shares of the Company's common stock to three newly hired employees of the Company, each as an inducement material to such employee's entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grants”).

CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-06-19 16:05:00

CAMBRIDGE, Mass. , June 19, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on June 15, 2026 (the "Grant Date"), the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 39,000 shares of the Company's common stock to three newly hired employees of the Company, each as an inducement material to such employee's entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the "Inducement Grants").

Discovr Radio to Embed Across All Four Days of CAMP Toronto in First Major Activation with Beatcave

2026-06-16 07:00:00

Live demo listening session to approve artists onto the platform in real time New “golden ticket” subscriptions reward breakout performers on the spot Studio takeover and on-site activations give creators direct access to Discovr Radio's AI powered artist promotion tools BOULDER, Colo., June 16, 2026 (GLOBE NEWSWIRE) -- Auddia Inc. (NASDAQ: AUUD) (“Auddia” or the “Company”), an AI first technology company that has built a proprietary AI platform for audio identification and classification to reinvent how consumers engage with audio and how artists get discovered, today announced that its Discovr Radio AI powered artist promotion platform will integrate across all four days of CAMP Toronto, the flagship songwriting camp and music conference hosted by partner Beatcave, taking place July 16-19, 2026.

New Analysis Strengthens Mercator Gold System and Confirms High-Grade BIF Continuity

2026-06-08 06:30:00

Canadian GoldCamps says Mercator resampling returned gold in 82% of samples, confirming mineralization continuity and new high-grade targets for 2026 work.

Mercator Gold Exploration Priorities & Strategy

2026-05-26 06:01:00

Company to advance NI 43-101 Technical Report; 2026 exploration campaign to follow up on promising historic work including high-grade intercepts of 5.6 metres of 4.87 g/t gold Vancouver, British Columbia, TheNewswire, May 26, 2026, Canadian GoldCamps Corp. (CSE: CAMP) (OTC: SMATF) (FSE: A68) is pleased to provide an update on its 2026 exploration strategy for the Mercator and Courcy gold projects located in the Caniapiscau district of northeastern Québec.

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

2026-05-21 16:05:00

CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on May 15, 2026 (the “Grant Date”), the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase 5,000 shares of the Company's common stock to a newly hired employee of the Company as an inducement material to such employee's entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).

CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder

2026-05-14 07:00:00

CMP-002 administration resulted in a statistically significant improvement in seizure phenotypes and parameters in a SYNGAP1 haploinsufficient mouse model

CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates

2026-05-07 20:11:42

CAMP4 Therapeutics Corporation (CAMP) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.62 per share a year ago.

Frequently Asked Questions

What is the current CAMP4 Therapeutics Corporation (CAMP) stock price?

CAMP4 Therapeutics Corporation(NASDAQ:CAMP) stock price is $4.45 in the last trading session. During the trading session, CAMP stock reached the peak price of $7.75 while $1.32 was the lowest point it dropped to. The percentage change in CAMP stock occurred in the recent session was --1.11% while the dollar amount for the price change in CAMP stock was -$-0.05.

CAMP's industry and sector of operation?

The NASDAQ listed CAMP is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of CAMP?

Kelly Gold | Chief Financial Officer
Leonard I. Zon | Founder & Chairman of Scientific Advisory Board
Richard A. Young | Founder & Independent Director
Joshua Mandel-Brehm | Chief Executive Officer, President & Director
Alla Sigova | Senior Vice President of Platform

How many employees does CAMP have?

Number of CAMP employees currently stands at 48. CAMP operates from One Kendall Square Bldg 1400 West, 3rd Floor, Cambridge, MA 02139, US.

Link for CAMP official website?

Official Website of CAMP is: https://www.camp4tx.com

How do I contact CAMP?

CAMP could be contacted at phone #617-651-8867 and can also be accessed through its website. CAMP operates from One Kendall Square Bldg 1400 West, 3rd Floor, Cambridge, MA 02139, US.

How many shares of CAMP are traded daily?

The average number of CAMP shares traded daily for last 3 months was 172K.

What is the market cap of CAMP currently?

The market value of CAMP currently stands at $94.52M with its latest stock price at $4.45